U.K. Doctors Can Prescribe Cannabis Now. They May Not Know How
(Bloomberg) -- The green wave of cannabis legalization is coming to the U.K.
Britain's government will officially allow some physicians to prescribe medical marijuana, beginning Thursday. It will take time to import a supply, and many doctors may not know how to use it, but the U.K.'s 66 million people add a significant new market for the booming global industry.
While Europe has lagged behind Canada and some U.S. states in legalization, sentiment around medical cannabis moved U.K. officials to act this year. Three-quarters of British people think doctors should be able to prescribe marijuana for medical purposes, according to a poll by YouGov in May. The issue heated up over the summer as parents of children who used the drug to treat seizures pressed the government for legalization.
In October, Home Secretary Sajid Javid announced that cannabis would become legal on Nov. 1 for specialist doctors, not general practitioners, to prescribe for any condition. Javid cited “heartbreaking cases involving sick children” as a motivation for the change.
Demand Expected
Medical cannabis will still face a number of restrictions. Doctors will need approval on a case-by-case basis before issuing a prescription. The Royal College of Physicians doesn't recommend cannabis for pain treatment, so patients may not be able to get it through the National Health Service for that purpose.
Photo Essay: America's First Cannabis-Based Medicine Is Made in England
Supply shouldn't be an issue, according to Cosmo Feilding Mellen, managing director at a British unit of Canopy Growth Corp. Companies will apply for import licenses in the coming weeks, he said. That should bring Canadian product to the market by the end of the year.
“Based on the clinical guidelines, we'll import as appropriately and quickly as possible,” he said by phone. “We expect there to be a huge demand, unmet demand for medicinal cannabis.”
Canopy will unroll a range of products derived from the plant, including oils and gel capsules, to meet the demand. Feilding Mellen expects any appropriately licensed pharmacy to be able to sell them.
The U.K. is the biggest producer of cannabis for medical and scientific purposes, according to the United Nations. GW Pharmaceuticals Plc, based in Cambridge, England, grows about 20 tons of cannabis annually at greenhouses the size of football fields.
The plants, genetically modified to remove psychoactive properties, are used to produce Epidiolex, a prescription drug for children with severe epilepsy. The U.S. Food and Drug Administration approved the treatment in June, making it the first prescription medicine derived from cannabis permitted to be sold in the U.S.
Educating Doctors
A major hurdle in the U.K. will be to get doctors familiar enough with the plant to prescribe it.
“The general public won't see a difference for a few months, until slowly but surely more doctors are willing to prescribe,” said Michael Barnes, a neurologist and medical cannabis advocate. Barnes, who co-authored a paper for the All Party Parliamentary Group for Drug Policy Reform on cannabis in 2016, first encountered it as a medicine years ago when he worked with multiple sclerosis patients who bought the drug illegally.
After hearing of its benefits from users, “I thought, ‘For heaven's sake, this is a medicine that does some good,'” Barnes said.
To get more doctors educated, Barnes will help launch a free online course on Monday through the London-based Academy of Medical Cannabis. The project was funded by Canadian company Aphria Inc. and the U.K.-based investment group European Cannabis Holdings but will operate independently of those organizations, Barnes said.
Relief Prospect
As the drug becomes available, some patients say they're looking forward to the prospect of relief.
“It's a life-changing moment for a lot of people,” said Jake Barrow, 31, of London.
Barrow has been left with pain and eating issues since he suffered a diaphragmatic hernia at birth. The only medication he's found that works is cannabis. With legalization, he looks forward to safe, professional access to an effective treatment.
“I need to be given the medicine and some guidance so I can learn how to use it properly,” Barrow said by phone. “I'll probably break down and cry when I get outside the pharmacy.”
--With assistance from Thomas Buckley.
To contact the reporter on this story: William Mathis in London at wmathis2@bloomberg.net
To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John Lauerman
©2018 Bloomberg L.P.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.